Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Karolína Perglerová"'
Autor:
Manja Meggendorfer, Andreia de Albuquerque, Niroshan Nadarajah, Tamara Alpermann, Wolfgang Kern, Kimberly Steuer, Karolína Perglerová, Claudia Haferlach, Susanne Schnittger, Torsten Haferlach
Publikováno v:
Haematologica, Vol 100, Iss 12 (2015)
Externí odkaz:
https://doaj.org/article/a31714b076c6497987c873c1467f9fd7
Autor:
Pedro Martin-Cabrera, Wolfgang Kern, Claudia Haferlach, Karolína Perglerová, Sabine Jeromin, Torsten Haferlach
Publikováno v:
Haematologica. 102:e125-e128
Autor:
Ursula Creutzig, Claudia Haferlach, Tamara Alpermann, Jutta Bradtke, Zuzana Zemanova, Mareike Rasche, Christian Thiede, Martin Zimmermann, Dirk Reinhardt, Joelle Tchinda, Christine von Neuhoff, Karolína Perglerová, Michael Dworzak
Publikováno v:
Cancer. 122:3821-3830
BACKGROUND: To obtain better insight into the biology of acute myeloid leukemia (AML) in various age groups, this study focused on the genetic changes occurring during a lifetime. METHODS: This study analyzed the relation between age and genetics fro
Autor:
Claudia Haferlach, Susanne Schnittger, Melanie Zenger, Karolína Perglerová, Torsten Haferlach, Wolfgang Kern, Anna Stengel
Publikováno v:
Genes, Chromosomes and Cancer. 55:82-94
T-cell prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell neoplasm with aggressive clinical course and short overall survival. So far, due to the rareness of this disease, genetic data are available only from individual cases or small cohor
Autor:
Torsten Haferlach, Kimberly Steuer, Tamara Alpermann, Manja Meggendorfer, Andreia Albuquerque, Claudia Haferlach, Karolína Perglerová, Wolfgang Kern, Susanne Schnittger, Nirsoshan Nadarajah
Publikováno v:
Haematologica. 100:e487-e490
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms associated with aberrant myeloid differentiation and ineffective hematopoiesis leading to cytopenias. In more than 20% of affected patients the MDS transforms into seconda
Acute promyelocytic leukemia (APL) occurs in about 5–30% of adult de novo AML and is characterized by the presence of the chromosomal translocation t(15;17)(q24;q21). The resulting PML-RARA chimeric gene involves the retinoic acid receptor alpha-(R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff3d34be2b03023ce894a67a440c6ed
https://europepmc.org/articles/PMC5451348/
https://europepmc.org/articles/PMC5451348/
Autor:
Torsten Haferlach, Claudia Haferlach, Simone Weber, Wolfgang Kern, Karolína Perglerová, Tamara Alpermann, Susanne Schnittger
Publikováno v:
British journal of haematology. 175(5)
High BAALC gene expression has been associated with poor prognosis in cytogenetically normal acute myeloid leukaemia (CN-AML) and has been suggested as a suitable marker for assessing minimal residual disease (MRD). The purpose of this study was to s
Autor:
Anna, Stengel, Wolfgang, Kern, Melanie, Zenger, Karolína, Perglerová, Susanne, Schnittger, Torsten, Haferlach, Claudia, Haferlach
Publikováno v:
Genes, chromosomescancer. 55(1)
T-cell prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell neoplasm with aggressive clinical course and short overall survival. So far, due to the rareness of this disease, genetic data are available only from individual cases or small cohor
Autor:
Ilona Slepičková, Vanda Indráková, Zdeňka Vlčková, Veronika Nedvědová, Eva Lavická, Michaela Hrabíková, Monika Koudova, Karolína Perglerová, Michaela Rímska, Martina Bittóová, Renata Alanova, Monika Hlaváčová, Lucie Pavlíčková
Publikováno v:
The EPMA Journal
The pyrimidine analogue 5-fluorouracil (5-FU) is widely used for chemotherapy of many solid tumors, such as colorectal, breast, head/neck, ovarian and skin cancer. More than 80% of administered 5-FU is rapidly detoxified in the liver via a multistep
Autor:
Wolfgang Kern, Wenke Worseg, Karolína Perglerová, Manja Meggendorfer, Torsten Haferlach, Claudia Haferlach
Publikováno v:
Blood. 128:1710-1710
Introduction: Investigation of minimal residual disease (MRD) using NPM1 as a target has been proven to be of importance in AML. Guidelines for best schedules and implication on clinical use need to be defined. Aims: To better define the clinical imp